Drug & Supplement Interactions

Cannabidiol (CBD) + Rocuronium

Brand name of Rocuronium

  • Zemuron

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated October 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line No Known Interaction

We found no known interaction between Cannabidiol (CBD) and Rocuronium in our sources.

This also applies to Zemuron, a brand name of rocuronium.

Still Worth Knowing

  • Shared side effects: Although there is no interaction, both can cause some of the same side effects. Taken together, those side effects might add up, and a new symptom can be harder to pin on one or the other.
See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Cannabidiol (CBD) with Rocuronium. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Cannabidiol (CBD) and Rocuronium Interaction Check

No Known Interaction Found

We did not find a documented interaction between Rocuronium and Cannabidiol (CBD) in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

How We Checked

Why No Interaction Is Listed for Rocuronium

We sort drugs into categories, such as blood thinners or antibiotics, and many supplement interactions are recorded for a whole category rather than for one drug. So we checked every category Rocuronium is in against every category Cannabidiol (CBD) has a known interaction with.

1Category Rocuronium Is In
  • Skeletal Muscle Relaxants No Cannabidiol (CBD) Record
39Drug Categories Cannabidiol (CBD) Interacts With
Show all 39 categories

No overlap. Rocuronium is in none of the 39 categories Cannabidiol (CBD) interacts with, so no record links the two.

Still wondering about combining Cannabidiol (CBD) and Rocuronium? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share
What to Watch For

Side Effects Cannabidiol (CBD) and Rocuronium Have in Common

7 side effects show up for both Cannabidiol (CBD) and Rocuronium.

  • Each has separately been linked to the effects below. Taken together, they might add up: the same side effect from two sources might be more likely or stronger. No study of the two together says by how much.
  • If one turns up, it can be harder to tell which one is behind it, so tell your pharmacist you take both.
  • One of them is worth acting on rather than waiting out, marked below.
  • Raised blood pressure Worth Acting On Additional detail

    Cannabidiol (CBD)

    Orally, cannabidiol has been associated with cardiovascular effects in some reports. In one clinical study, some patients experienced hypotension, orthostatic hypotension, and lightheadedness. Also, cannabidiol has also been linked to hypertension, palpitations, and tachycardia.

    Source: , the clinical database we license.

    6 references cited
    1. 89700. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. PubMed
    2. 115826. Velayudhan L, Pisani S, Dugonjic M, McGoohan K, Bhattacharyya S. Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference. Age Ageing 2024;53(11):afae261. PubMed
    3. 105493. Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020. Am J Emerg Med. 2021;48:218-223. PubMed
    4. 110248. Perez-Vilar S, Karami S, Long K, Leishear K. Cannabidiol exposures in the United States, National Poison Data System, July 2014-June 2021. Clin Toxicol (Phila) 2022. PubMed
    5. 61832. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. PubMed
    6. 89675. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36(6):1219-26. PubMed

    Rocuronium

    Source: Rocuronium’s

    It lists this side effect in its Adverse Reactions section.

    Read Rocuronium’s label on DailyMed ›
  • Low blood pressure / A fast or pounding heartbeat reported in 9.6% of FDA reports for Rocuronium Additional detail

    Cannabidiol (CBD)

    Recorded for Cannabidiol (CBD) in the same Natural Medicines adverse-effect record shown under Raised blood pressure above.

    Rocuronium

    Source: Rocuronium’s

    It lists this side effect in its Adverse Reactions section. Voluntary reports to the FDA mention it too.

    Read Rocuronium’s label on DailyMed ›
  • Itching / A skin rash Additional detail

    Cannabidiol (CBD)

    Orally, cannabidiol might cause rare skin reactions. In a clinical study in healthy adults, 2 cases of skin reactions, one severe and one mild, were reported. These and 2 additional cases were reported in a follow-up publication specific to cannabidiol-induced skin rash. The rash occurred in 4 female patients after taking oral cannabidiol 300 mg daily for up to 9 days.

    Source: , the clinical database we license.

    5 references cited
    1. 105696. Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone
    2. 109178. Souza JDS, Fassoni-Ribeiro M, Batista RM, et al. Case report: Cannabidiol-induced skin rash: A case series and key recommendations. Front Pharmacol 2022;13:881617. PubMed
    3. 110244. Souza JDR, Pacheco JC, Rossi GN, et al. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 2022;14(12):2598. PubMed
    4. 113032. Fazlollahi A, Zahmatyar M, ZareDini M, et al. Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis. JAMA Netw Open 2023;6(4):e239126. PubMed
    5. 110243. Berry-Kravis E, Hagerman R, Budimirovic D, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord 2022;14(1):56. PubMed

    Rocuronium

    Source: Rocuronium’s

    It lists this side effect in its Adverse Reactions section.

    Read Rocuronium’s label on DailyMed ›
  • Vomiting Additional detail

    Cannabidiol (CBD)

    Orally, cannabidiol oil has been associated with rare respiratory depression and increased odds of pneumonia. In a case report, a 56-year-old obese male presented to the emergency room with severe respiratory depression 3 hours after consuming two packages of gummies labeled to contain cannabidiol 370 mg. Symptoms included respiratory acidosis, slurred speech, bradycardia, and vomiting.

    Source: , the clinical database we license.

    6 references cited
    1. 103029. Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12(4):e7688. PubMed
    2. 103031. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020. PubMed
    3. 106631. Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(9):2228-2239. PubMed
    4. 106633. Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(10):2505-2517. PubMed
    5. 110247. Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol 2022. PubMed
    6. 61759. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed

    Rocuronium

    Source: Rocuronium’s

    It lists this side effect in its Adverse Reactions section.

    Read Rocuronium’s label on DailyMed ›
  • Nausea Additional detail

    Cannabidiol (CBD)

    Orally, cannabidiol has caused dry mouth and altered taste perception in some patients in clinical research. In children and adults, cannabidiol oil has caused mild to moderate diarrhea, decreased appetite, weight loss, nausea, and vomiting. Diarrhea, decreased appetite, and weight loss or weight gain have been reported at a higher frequency with doses greater than 15-20 mg/kg daily.

    Source: , the clinical database we license.

    6 references cited
    1. 89700. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. PubMed
    2. 105559. Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. PubMed
    3. 109177. Berger M, Li E, Rice S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial. J Clin Psychiatry 2022;83(5):21m14130. PubMed
    4. 110245. Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond) 2022;2(1): PubMed
    5. 110249. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.
    6. 115826. Velayudhan L, Pisani S, Dugonjic M, McGoohan K, Bhattacharyya S. Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference. Age Ageing 2024;53(11):afae261. PubMed

    Rocuronium

    Source: Rocuronium’s

    It lists this side effect in its Adverse Reactions section.

    Read Rocuronium’s label on DailyMed ›

Reported for Cannabidiol (CBD) but not commonly for Rocuronium: liver problems, dependence or withdrawal symptoms, reduced appetite and trouble concentrating.

Note: Effects for Rocuronium come from the Adverse Reactions section of its FDA label; effects for Cannabidiol (CBD) come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 11,714 voluntary FDA FAERS reports for Rocuronium that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. The two sources word some effects differently, so we match them by meaning.

If You Decide to Take Both
  • Add one new thing at a time, and note the date you started it.
  • A start date turns “I’ve been feeling off” into something a pharmacist can work with.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.

Your Whole Routine

Your Other Medicines and Supplements

Keep It in Perspective

Cannabidiol (CBD) Does Interact With Other Medications

Cannabidiol (CBD) has 1,053 moderate known drug interactions in our database — Rocuronium isn’t one of them. If you take anything else, check it against the full list below.

Taking Anything Else?

Check Another of Your Medications Against Cannabidiol (CBD)

Covers the 2,830 medications we’ve checked against Cannabidiol (CBD). Pick one to open its full report.

Alternatives for the Same Use

Other Supplements Studied for Epilepsy, and How They Mix With Rocuronium

Choosing a supplement while you take Rocuronium? Here are other options studied for epilepsy, and whether each has a documented interaction with Rocuronium.

1 of them has a documented interaction with Rocuronium: Magnesium (moderate).

2 other supplements have at least some evidence of a benefit for epilepsy. Cannabidiol (CBD) itself is graded for it.

  • Magnesium Graded Moderate
  • Piracetam Graded No Known Interaction

The grades come from the Natural Medicines database and describe the research so far, not a recommendation, and none of these supplements replaces a prescribed medicine.

Everything Else You Take

See Every Supplement That Interacts With Rocuronium

Take other supplements too? 3 supplements have a documented interaction with Rocuronium, each explained on its page.

By severity: 1 major and 2 moderate.

The Most Serious There Right Now:

Open the Rocuronium interaction pageEvery supplement checked against Rocuronium, ranked by severity
Supplement

About Cannabidiol (CBD)

CBD is a compound from the cannabis (hemp) plant that does not cause a 'high.' It has strong evidence only for certain rare seizure disorders (as a prescription drug), while most other popular uses are still backed by limited or early research. Product quality varies a lot, so talk with your pharmacist or doctor before using it, especially if you take other medicines.

Full Cannabidiol (CBD) guide: uses, dosage, safety and every interaction

On Its Own

Cannabidiol (CBD) Safety

Safety at a Glance

How Cannabidiol (CBD) Is Rated

  • Cannabidiol (CBD) Overall

    Use caution

    CBD is generally well tolerated but can cause side effects and quality varies between products.

  • Pregnancy

    Possibly Unsafe

    When used orally. The US Food and Drug Administration (FDA) strongly advises against the use of cannabidiol during pregnancy.

    Read the full pregnancy detail ↓
  • Breastfeeding

    Possibly Unsafe

    When used orally. The US Food and Drug Administration (FDA) strongly advises against the use of cannabidiol during pregnancy.

    Read the full breastfeeding detail ↓

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center), with the full detail in the next card.

Special Populations

Cannabidiol (CBD) in Pregnancy & Breastfeeding

Pregnancy And Lactation Possibly Unsafe

When used orally. The US Food and Drug Administration (FDA) strongly advises against the use of cannabidiol during pregnancy. Cannabidiol products might contain delta-9-tetrahydrocannabinol (THC) or other contaminants such as pesticides, heavy metals, bacteria, and fungus, which can be dangerous to the child. Also, animal research shows that high levels of cannabidiol can damage the reproductive system of male offspring.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Cannabidiol (CBD)

Browse every other medication we’ve checked against Cannabidiol (CBD) — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
1,053Moderate
0Minor
1,776No known interaction
Moderate

Moderate: 1,053 interactions

Showing 60 of 1,053 moderate interactions — see all 1,053 on the Cannabidiol (CBD) page.

No Interaction 1,776 drugs checked — show the list

We also checked Cannabidiol (CBD) against these medications and found no known interaction in our sources. Open any page to confirm.

Showing 60 of the 1,776 medications checked with no known interaction, the most looked-up first — see the full Cannabidiol (CBD) list.

How Much People Look This Up

Where Cannabidiol (CBD) and Rocuronium Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Cannabidiol (CBD)
Top 25%

#311 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication Rocuronium
Top 25%

#500 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Cannabidiol (CBD) and Rocuronium Together: Common Questions

Can you take Cannabidiol (CBD) with Rocuronium?
We do not list a known interaction between Cannabidiol (CBD) and Rocuronium. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Can you take Cannabidiol (CBD) with Zemuron?
Zemuron is a brand name of rocuronium, so the answer is the same as for rocuronium. We do not list a known interaction between Cannabidiol (CBD) and Rocuronium. Everything on this page applies to Zemuron too.
Do Cannabidiol (CBD) and Rocuronium have any of the same side effects?
Yes — our sources link each of them separately to 7 of the same effects. That is not a documented interaction, but taken together the same side effect from two sources might be more likely or stronger; no study of the two together says by how much. And if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
How was the Cannabidiol (CBD) and Rocuronium combination checked?
Interactions in our licensed database are recorded against drug classes. Rocuronium is filed under 1 classification, and Cannabidiol (CBD) has documented interactions with 39 drug classes — none of Rocuronium's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Do other supplements studied for epilepsy interact with Rocuronium?
1 of the 2 other supplements the Natural Medicines database grades as having some evidence of a benefit for epilepsy has a documented interaction with Rocuronium: Magnesium (moderate). A grade is the research so far, not a recommendation, and no known interaction is not proof of safety; ask your pharmacist before adding one.
Does Cannabidiol (CBD) interact with any other medications?
Yes. Cannabidiol (CBD) has 1,053 documented drug interactions in our database — Rocuronium is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Rocuronium interact with any supplements?
Yes. Rocuronium has documented interactions with 3 supplements in our database — Cannabidiol (CBD) is not one of them. The Rocuronium interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 21 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 21 references
  1. 61759. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed
  2. 61832. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. PubMed
  3. 89675. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36(6):1219-26. PubMed
  4. 89700. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. PubMed
  5. 103029. Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12(4):e7688. PubMed
  6. 103031. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020. PubMed
  7. 105493. Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020. Am J Emerg Med. 2021;48:218-223. PubMed
  8. 105559. Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. PubMed
  9. 105696. Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone
  10. 106631. Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(9):2228-2239. PubMed
  11. 106633. Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(10):2505-2517. PubMed
  12. 109177. Berger M, Li E, Rice S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial. J Clin Psychiatry 2022;83(5):21m14130. PubMed
  13. 109178. Souza JDS, Fassoni-Ribeiro M, Batista RM, et al. Case report: Cannabidiol-induced skin rash: A case series and key recommendations. Front Pharmacol 2022;13:881617. PubMed
  14. 110243. Berry-Kravis E, Hagerman R, Budimirovic D, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord 2022;14(1):56. PubMed
  15. 110244. Souza JDR, Pacheco JC, Rossi GN, et al. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 2022;14(12):2598. PubMed
  16. 110245. Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond) 2022;2(1): PubMed
  17. 110247. Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol 2022. PubMed
  18. 110248. Perez-Vilar S, Karami S, Long K, Leishear K. Cannabidiol exposures in the United States, National Poison Data System, July 2014-June 2021. Clin Toxicol (Phila) 2022. PubMed
  19. 110249. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.
  20. 113032. Fazlollahi A, Zahmatyar M, ZareDini M, et al. Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis. JAMA Netw Open 2023;6(4):e239126. PubMed
  21. 115826. Velayudhan L, Pisani S, Dugonjic M, McGoohan K, Bhattacharyya S. Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference. Age Ageing 2024;53(11):afae261. PubMed

All 100 references behind our Cannabidiol (CBD) records are listed in the Cannabidiol (CBD) guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 15, 2026. The Cannabidiol (CBD) and Rocuronium records this page draws on were last updated October 13, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Cannabidiol (CBD) and Rocuronium?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.